The original concept of synthetic lethality between PARP inhibitors and breast and ovarian cancer mutations in BRCA1/2 has now expanded to include a range of cancer types exhibiting homologous recombination deficiency and replication stress. The gene discussed is BRCA1; the disease is cancer.